Cargando…
Applying artificial intelligence for cancer immunotherapy
Artificial intelligence (AI) is a general term that refers to the use of a machine to imitate intelligent behavior for performing complex tasks with minimal human intervention, such as machine learning; this technology is revolutionizing and reshaping medicine. AI has considerable potential to perfe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642413/ https://www.ncbi.nlm.nih.gov/pubmed/34900525 http://dx.doi.org/10.1016/j.apsb.2021.02.007 |
_version_ | 1784609678549843968 |
---|---|
author | Xu, Zhijie Wang, Xiang Zeng, Shuangshuang Ren, Xinxin Yan, Yuanliang Gong, Zhicheng |
author_facet | Xu, Zhijie Wang, Xiang Zeng, Shuangshuang Ren, Xinxin Yan, Yuanliang Gong, Zhicheng |
author_sort | Xu, Zhijie |
collection | PubMed |
description | Artificial intelligence (AI) is a general term that refers to the use of a machine to imitate intelligent behavior for performing complex tasks with minimal human intervention, such as machine learning; this technology is revolutionizing and reshaping medicine. AI has considerable potential to perfect health-care systems in areas such as diagnostics, risk analysis, health information administration, lifestyle supervision, and virtual health assistance. In terms of immunotherapy, AI has been applied to the prediction of immunotherapy responses based on immune signatures, medical imaging and histological analysis. These features could also be highly useful in the management of cancer immunotherapy given their ever-increasing performance in improving diagnostic accuracy, optimizing treatment planning, predicting outcomes of care and reducing human resource costs. In this review, we present the details of AI and the current progression and state of the art in employing AI for cancer immunotherapy. Furthermore, we discuss the challenges, opportunities and corresponding strategies in applying the technology for widespread clinical deployment. Finally, we summarize the impact of AI on cancer immunotherapy and provide our perspectives about underlying applications of AI in the future. |
format | Online Article Text |
id | pubmed-8642413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86424132021-12-09 Applying artificial intelligence for cancer immunotherapy Xu, Zhijie Wang, Xiang Zeng, Shuangshuang Ren, Xinxin Yan, Yuanliang Gong, Zhicheng Acta Pharm Sin B Review Artificial intelligence (AI) is a general term that refers to the use of a machine to imitate intelligent behavior for performing complex tasks with minimal human intervention, such as machine learning; this technology is revolutionizing and reshaping medicine. AI has considerable potential to perfect health-care systems in areas such as diagnostics, risk analysis, health information administration, lifestyle supervision, and virtual health assistance. In terms of immunotherapy, AI has been applied to the prediction of immunotherapy responses based on immune signatures, medical imaging and histological analysis. These features could also be highly useful in the management of cancer immunotherapy given their ever-increasing performance in improving diagnostic accuracy, optimizing treatment planning, predicting outcomes of care and reducing human resource costs. In this review, we present the details of AI and the current progression and state of the art in employing AI for cancer immunotherapy. Furthermore, we discuss the challenges, opportunities and corresponding strategies in applying the technology for widespread clinical deployment. Finally, we summarize the impact of AI on cancer immunotherapy and provide our perspectives about underlying applications of AI in the future. Elsevier 2021-11 2021-02-11 /pmc/articles/PMC8642413/ /pubmed/34900525 http://dx.doi.org/10.1016/j.apsb.2021.02.007 Text en © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Xu, Zhijie Wang, Xiang Zeng, Shuangshuang Ren, Xinxin Yan, Yuanliang Gong, Zhicheng Applying artificial intelligence for cancer immunotherapy |
title | Applying artificial intelligence for cancer immunotherapy |
title_full | Applying artificial intelligence for cancer immunotherapy |
title_fullStr | Applying artificial intelligence for cancer immunotherapy |
title_full_unstemmed | Applying artificial intelligence for cancer immunotherapy |
title_short | Applying artificial intelligence for cancer immunotherapy |
title_sort | applying artificial intelligence for cancer immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642413/ https://www.ncbi.nlm.nih.gov/pubmed/34900525 http://dx.doi.org/10.1016/j.apsb.2021.02.007 |
work_keys_str_mv | AT xuzhijie applyingartificialintelligenceforcancerimmunotherapy AT wangxiang applyingartificialintelligenceforcancerimmunotherapy AT zengshuangshuang applyingartificialintelligenceforcancerimmunotherapy AT renxinxin applyingartificialintelligenceforcancerimmunotherapy AT yanyuanliang applyingartificialintelligenceforcancerimmunotherapy AT gongzhicheng applyingartificialintelligenceforcancerimmunotherapy |